InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...
SHA: 688428
InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum
Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...
InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received approval from...
Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the...
InnoCare Pharma’s ICP-488 Shows Promising Results in Phase II Psoriasis Study
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...
InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...
InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025
InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its...
InnoCare Pharma’s TYK2 Inhibitor ICP-332 Receives FDA IND Approval for Atopic Dermatitis
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company based in China has announced that...
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428),...
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report...
InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first...
InnoCare Pharma Receives IND Approval in China for BCL2 Inhibitor Combo Therapy
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has announced that it has...
InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA
InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...
InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248
InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...
InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...
InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based...
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...